OrbiMed’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

OrbiMed’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-90,000	Closed	-$1.37M	–	141
2016 Q3	$1.37M	Buy	+90,000	New	+$3.64M	0.02%	128

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

OrbiMed's ITCI Position: Q1 2025 in Review

OrbiMed sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 163,000 shares — an estimated $13.6M sold.

OrbiMed first reported a position in ITCI in Q1 2016 and held it in 3 quarters. The position peaked at $34.4M in Q2 2016. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

OrbiMed reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
OrbiMed sold 163,000 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $13.6M.
OrbiMed first reported a position in Intra-Cellular Therapies Inc. in Q1 2016 and held it in 3 quarters.
OrbiMed's Intra-Cellular Therapies Inc. position peaked at $34.4M in Q2 2016.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on OrbiMed's 13F filing for Q1 2025, filed 15 May 2025.